Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Rafael Holdings, Inc. (RFL) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/11/2018 GN Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (devimistat) in Combination with Modified FOLFIRINOX as First Line Treatment for Patients with Metastatic Pancreatic Cancer
12/10/2018 10-Q Quarterly Report for the period ended October 31, 2018
12/10/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports First Quarter Fiscal Year 2019 Results"
12/06/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentations"
11/29/2018 GN Rafael Pharmaceuticals Announces Initiation of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613 (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
11/27/2018 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/21/2018 8-K Other Events
11/15/2018 PRE 14A Form PRE 14A - Other preliminary proxy statements:
11/09/2018 8-K Other Events
10/17/2018 10-K/A Annual Report for the period ended July 31, 2018 [amend]
10/15/2018 10-K Annual Report for the period ended July 31, 2018
10/15/2018 8-K Quarterly results
10/15/2018 GN Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
09/27/2018 8-K Quarterly results
09/14/2018 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Disposed of 787,163 shares @ $0
Acquired 787,163 shares @ $0
Disposed of 97,491 shares @ $0
Acquired 97,491 shares @ $0
Disposed of 32,711 shares @ $0
Acquired 32,711 shares @ $0
Disposed of 225,556 shares @ $0
Acquired 225,556 shares @ $0
09/07/2018 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Release"
08/16/2018 GN Rafael Pharmaceuticals Receives FDA Orphan Drug Designation of CPI-613 for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
08/13/2018 GN Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma
07/20/2018 4 ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Paid exercise price by delivering 643 shares @ $9.37, valued at $6k
06/11/2018 10-Q Quarterly Report for the period ended April 30, 2018
06/11/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Third Quarter Fiscal Year 2018 Results"
05/22/2018 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/01/2018 8-K Other Events
04/12/2018 SC 13D JONAS HOWARD S reports a 20.3% stake in RAFAEL HOLDINGS, INC.
03/29/2018 4 MASON JOYCE J (FORMER DIRECTOR) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 3,000 shares @ $0
03/29/2018 4 ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 58,200 shares @ $0
03/29/2018 4 Polinsky David (CFO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Granted 8,000 shares @ $0
03/28/2018 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Disposed of 787,163 shares @ $0
Disposed of 11,639,901 shares @ $0
03/28/2018 4 IDT CORP (10% Owner) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Disposed of 787,163 shares @ $0
Disposed of 11,639,901 shares @ $0
03/27/2018 10-12G/A Form 10-12G/A - Registration of securities [Section 12(g)]: [Amend]
03/14/2018 3 GREENBERG STEPHEN M (Director) has filed a Form 3 on Rafael Holdings, Inc.
03/14/2018 3 WEISS MICHAEL J (Director) has filed a Form 3 on Rafael Holdings, Inc.
03/14/2018 3 PASCHE BORIS C (Director) has filed a Form 3 on Rafael Holdings, Inc.
03/12/2018 10-Q Quarterly Report for the period ended January 31, 2018
  Next >>

Rocket Data Systems, Inc. © 2018 | Contact Us | Data Disclaimer | Terms of Use | Privacy